Vanguard Capital Management
PLYX icon

Vanguard Capital Management’s Polaryx Therapeutics Inc PLYX Stock Holding History

Vanguard Capital Management’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.43M Sell
1,655,833
-2,039
-0.1% -$4.44K ﹤0.01% 3203
2026
Q2 		$4.41M Sell
1,657,872
-516
-0% -$2.02K ﹤0.01% 3170
2026
Q1 		$12.5M Buy
+1,658,388
New +$10.7M ﹤0.01% 2609

Other funds holding PLYX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $87.3B AUM 22.01% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $225B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Vanguard Capital Management's PLYX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Polaryx Therapeutics Inc (PLYX) stake by 0.12% in Q3 2026, selling an estimated $4.44K and leaving 1,655,833 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3203.

Vanguard Capital Management first reported a position in PLYX in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.5M in Q1 2026. 11 funds tracked by Wall St. Rank hold PLYX as of Q3 2026.

  • Vanguard Capital Management held 1,655,833 shares of Polaryx Therapeutics Inc worth $3.43M as of Q3 2026.
  • Vanguard Capital Management sold 2,039 Polaryx Therapeutics Inc shares in Q3 2026, an estimated $4.44K.
  • Polaryx Therapeutics Inc made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3203 holding.
  • Vanguard Capital Management first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Polaryx Therapeutics Inc position peaked at $12.5M in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.